AEON AEON Biopharma Inc.

USD 1.40 0.00 0
Icon

AEON Biopharma Inc. (AEON) Stock Analysis and Price Targets

COMMON STOCK | Biotechnology | NYE
stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

Strong Buy

Top Analyst
Rating
stockTargetAdvisor

Very Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

USD 1.40

0.00 (0.00)%

USD 0.05B

0.19M

USD 9.00(+542.86%)

N/A

Icon

AEON

AEON Biopharma Inc. (USD)
COMMON STOCK | NYE
USD 1.40
0.00 0
Take a Tour
stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

Strong Buy

Top Analyst
Rating
stockTargetAdvisor

Very Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

USD 0.05B

N/A

USD 1.40

AEON Biopharma Inc. (AEON) Stock Forecast

Show ratings and price targets of :
USD 9.00
(+542.86%)

Based on the AEON Biopharma Inc. stock forecast from 1 analysts, the average analyst target price for AEON Biopharma Inc. is USD 9.00 over the next 12 months. AEON Biopharma Inc.’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of AEON Biopharma Inc. is Very Bearish, which is based on 0 positive signals and 3 negative signals. At the last closing, AEON Biopharma Inc.’s stock price was USD 1.40. AEON Biopharma Inc.’s stock price has changed by +43.21% over the past week, +0.72% over the past month and 0% over the last year.

No recent analyst target price found for AEON Biopharma Inc.
No recent average analyst rating found for AEON Biopharma Inc.

Company Overview AEON Biopharma Inc.

AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoin...Read More

N/A

N/A

10

December

USD

USA

Adjusted Closing Price for AEON Biopharma Inc. (AEON)

Loading...

Unadjusted Closing Price for AEON Biopharma Inc. (AEON)

Loading...

Share Trading Volume for AEON Biopharma Inc. Shares

Loading...

Compare Performance of AEON Biopharma Inc. Shares

Symbol Capital Gain Dividend Return Total Return
Loading...
Loading...

Technical Indicators for AEON

Assets

Top Holdings

Top Sectors

Top Regions

Stocks Similar To AEON Biopharma Inc. (Sector: Biotechnology )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
NVO
Novo Nordisk A/S 0.00 (0.00%) USD634.05B 49.43 4.92

ETFs Containing AEON

Symbol Name AEON's Weight Expense Ratio Price(Change) Market Cap
no data

Frequently Asked Questions About AEON Biopharma Inc. (AEON) Stock

Based on ratings from 1 analysts AEON Biopharma Inc.'s stock is Strong Buy. Stock Target Advisor's fundamental analysis is Very Bearish. The stock has 4 buy, sell and hold ratings.

Unfortunately we do not have enough data on AEON's stock to indicate if its a good dividend stock.

Based on targets from 1 analysts, the average taret price for AEON is USD 9.00 over the next 12 months. The maximum analyst target price is USD 18 while the minimum anlayst target price is USD 6.

Unfortunately we do not have enough data on AEON's stock to indicate if its overvalued.

The last closing price of AEON's stock was USD 1.40.

The most recent market capitalization for AEON is USD 0.05B.

Based on targets from 1 analysts, the average taret price for AEON is projected at USD 9.00 over the next 12 months. This means that AEON's stock price may go up by +542.86% over the next 12 months.

We can't find any ETFs which contains AEON Biopharma Inc.'s stock.

As per our most recent records AEON Biopharma Inc. has 10 Employees.

Sorry we do not have any infomation available on AEON Biopharma Inc.'s address.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...